{"schema_version":"secwatch.filing_event.v1","accession":"0001096906-21-001665","form_type":"8-K","ticker":"UTMD","cik":"0000706698","company_name":"UTAH MEDICAL PRODUCTS INC","filed_at":"2021-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.511746+00:00","generated_at":"2026-06-30T03:28:01.489915+00:00","sec_items":["2.02","9.01","99.1"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"UTMD Q2 net income up 161%, EPS $0.937; revenue $12.6M (+43%); guides FY EBITDA ~$25M","bullets":["Q2 revenue $12.6M (+43% YoY); domestic +46%, OUS +40%; constant-currency sales +40%.","GAAP EPS $0.937 (up 161%); non-GAAP (ex-UK DTL) EPS $1.044 (up 148%).","Operating income $4.765M (+141%); gross margin 61.8% vs 56.3% a year ago.","Management likely expects FY2021 adjusted EBITDA of ~$25M; TTM EBITDA $24.0M.","Cash $59.5M, no debt; quarterly dividend $0.285/share (up from $0.280)."],"urls":{"canonical":"https://secwatch.observer/filing/0001096906-21-001665","json":"https://secwatch.observer/filing/0001096906-21-001665.json","markdown":"https://secwatch.observer/filing/0001096906-21-001665.md","text":"https://secwatch.observer/filing/0001096906-21-001665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/706698/000109690621001665/0001096906-21-001665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/706698/000109690621001665/utmd-20210722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T03:28:01.489915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}